Home Hot keywords

Search Modes

Search Results

Margetuximab
Choose what you’re giving feedback on
Margetuximab
Medication

Images

Description

Margetuximab, sold under the brand name Margenza, is a chimeric IgG monoclonal antibody medication against HER2 used for the treatment of cancer. Wikipedia
Target: HER2
Other names: margetuximab-cmkb, MGAH22
People also ask
Dec 16, 2020On December 16, 2020, FDA approved margetuximab-cmkb (MARGENZA, MacroGenics) in combination with chemotherapy, for the treatment of adult ...
by HS Rugo2021Cited by 60Margetuximab is a chimeric, Fc-engineered, immune-activating anti-ERBB2 immunoglobulin G1 (IgG1) monoclonal antibody that shares epitope ...
MARGENZA is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast ...
Margetuximab is an investigational, Fc engineered HER2-directed monoclonal antibody. Margetuximab-cmkb binds to the extracellular domain of the human ...
May 10, 2021Margetuximab is a novel anti-HER2 IgG1 monoclonal antibody similar to trastuzumab, but it has an engineered Fc portion to increase affinity for ...
Jan 25, 2021On December 16, the U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb (Margenza) in combination with chemotherapy for the ...
Margetuximab, sold under the brand name Margenza, is a chimeric IgG monoclonal antibody medication against HER2 used for the treatment of cancer.
Trade names: Margenza
CAS Number: 1350624-75-7
Pregnancy category: : Not recommended. Margetuximab can cause fetal harm when ...
Margetuximab-cmkb (Margenza) is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic ...
96413-hyphen96417: Chemotherapy administration, intravenous infusion technique
Sep 21, 2021When we talk about the mechanism of action of margetuximab, it's a bispecific monoclonal antibody, and it has ...
This phase II trial investigates how well paclitaxel and pertuzumab with margetuximab or trastuzumab works in treating patients with HER2-positive stage II-III ...

google search trends